pure_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
  Date of Report (Date of earliest event reported):  March 25, 2011
 
 
PURE BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)

California
0-21019
33-0530289
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
     
 
1725 Gillespie Way, El Cajon, California 92020
(Address of principal executive offices)(Zip Code)

(619) 596 8600
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report.)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
  
o
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-  2(b))
o
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-  4(c))
o
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


 
 
 
 
 
 
Item 5.02 Departure of Directors of Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
 
As previously reported, on March 7, 2011, Andrew Buckland resigned as the Chief Financial Officer of PURE Bioscience, Inc.. Mr. Buckland’s last day with PURE Bioscience, Inc. was Friday, March 25, 2011.
 
 
 
 

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 PURE Bioscience, Inc.
  
       
Dated: March 28, 2011
By:
 /s/ Michael L. Krall
  
   
 Michael L. Krall
  
   
 President and Chief Executive  Officer